<DOC>
	<DOC>NCT01771588</DOC>
	<brief_summary>It it is hypothesized that the growth of preterm infants receiving a new human milk fortifier will be equal or superior to the growth of preterm infants receiving a currently marketed human milk fortifier with a lower protein content.</brief_summary>
	<brief_title>Human Milk Fortifier - Growth Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<criteria>Birth weight ≤1500 g AND/OR gestational age ≤32 weeks (determined by maternal dates, fetal ultrasound, Dubowitz/Ballard examination or a combination thereof) Male or female Tolerating an enteral intake of human milk, donor milk or a combination at ≥100 mL/kg/d for ≥ 24 h Subject is anticipated to receive human milk, donor milk or a combination for ≥ 3 consecutive weeks after having achieved full fortification with volume intake contained between 150 and 180 mL/kg/d. Written informed consent has been obtained from the legal representative(s). Infants with current systemic disease Infants with a history of systemic disease Any congenital anomalies of the GI tract that significantly interfere with nutrition and growth or previous GI surgery. Small size for gestational age (SGA) body weight ≦ 5th percentile for that gestational age. Infants diagnosed with any inherent metabolic disease. Infants diagnosed with any chromosomic disease. Receiving any commercial formula supplementation to breast milk. Receiving steroids at the time of enrollment. Participation in another nutritional clinical trial that may affect outcomes of this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Month</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>